Physician profile
Arlynn Roper
NPI 1013980515
$3,356.24
in general payments reported to CMS, 2019-2025
24 companies · $654 in 2025
The $654 reported for 2025 was more than what 83% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $180 · 2020: $53.11 · 2021: $262 · 2022: $1,030 · 2023: $665 · 2024: $512 · 2025: $654.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,831.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,831.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $434.77 | 2019-2025 | Eysuvis, Tryptyr, Simbrinza |
| Bausch & Lomb Americas INC. | $384.28 | 2022-2025 | Prolensa, Miebo, Xiidra |
| Notal Vision, INC. | $364.64 | 2022 | |
| Tarsus Pharmaceuticals, INC. | $233.85 | 2024-2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $190.08 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $189.61 | 2022-2025 | Acthar |
| Sight Sciences, INC. | $188.58 | 2022-2023 | Omni Surgical System |
| Amgen INC. | $173.96 | 2024-2025 | Tepezza |
| Sun Pharmaceutical Industries INC. | $161.74 | 2021-2025 | Cequa |
| Rxsight INC | $156.79 | 2023-2024 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens |
| Dompe US, INC. | $120.75 | 2024-2025 | Oxervate |
| Allergan, INC. | $113.02 | 2019-2021 | |
| Glaukos Corporation | $104.77 | 2025 | Idosetr |
| Oyster Point Pharma, INC. | $90.17 | 2022-2025 | Tyrvaya, Ryzumvi |
| Ocular Therapeutix, INC. | $90.00 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $77.64 | 2021-2022 | |
| Horizon Therapeutics Plc | $67.51 | 2023 | Tepezza |
| Thea Pharma INC. | $54.50 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $43.89 | 2019-2021 | |
| Apellis Pharmaceuticals, INC. | $33.11 | 2025 | Syfovre |
| Harrow Eye, LLC | $32.90 | 2025 | Vevye |
| Visioneering Technologies, INC. | $20.34 | 2019 | |
| Shire North American Group INC | $15.47 | 2019 | |
| Abbvie INC. | $13.87 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arlynn Roper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.